NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









CellCentric

CellCentric

Private
CambridgeHealthcare & Life Scienceshttps://www.cellcentric.com/

Last Round

Series D

May 6, 2026

Est. Valuation

$900M

Total Funding Raised

$436.58M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

CellCentric is a biotechnology company that develops clinical-stage small-molecule inhibitors targeting p300/CBP for the treatment of multiple myeloma and other cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

biotechsmall molecule inhibitormultiple myelomainobrodibclinical trialsblood cancer treatmentp300/CBP inhibitordrug developmentoral cancer drughematology-oncologybiopharmadrug discoveryclinical-stage biotechout-licensingoncology pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CellCentric Comparables

Compare CellCentric with similar companies based on industry and business-model similarity.

CellCentric comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Karyopharm Therapeutics
78%
C4 Therapeutics
74%
Opna Bio
74%

CellCentric Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DMay 6, 2026
Series CMay 19, 2025
Series BJul 24, 2024
VC RoundSep 11, 2023
Convertible DebtJul 11, 2023
VC Round
Jan 26, 2022

Key People

Founding team and executive leadership

Will West

CEO

Executive Team

Debbie Haynes

Chief Operating Officer

Executive Team

CellCentric Investors

Notable investors and investment history

CellCentric investors
InvestorRounds
Avego ManagementSeries D, Series C
Forbion Capital PartnersSeries C
RA Capital ManagementSeries D, Series C, Series B
Future Planet Capital RegionalGrant
ForbionSeries D, Series C
BrightEdgeSeries C, Series B, VC Round
Morningside VenturesVC Round, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 6, 2026

    $220M round led by Venrock.

  • Dec 19, 2025

    Inobrodib enters Phase 3 trial for multiple myeloma and other cancers.

CellCentric Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CellCentric Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CellCentric's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range56
Year Founded2004
Last FundingMay 6, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.